Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Clinical trial NCT04976634 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04976634
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-18
- Primary completion
- 2027-03-22
- Enrollment
- 730
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.